New THC Microdose Drug Eases Chronic Back Pain in Clinical Trial

A new experimental drug containing microdoses of THC has shown promise in reducing chronic back pain. Developed by German pharmaceutical company Vertanical, the medication was tested in a recent clinical trial. Results suggest it could offer relief without the risks linked to traditional painkillers.

The study focused on patients suffering from persistent lower-back pain, a condition affecting millions worldwide. Those who received the drug reported an average pain reduction of nearly 2 points on an 11-point scale, compared to a placebo group. Beyond pain relief, participants also noted better sleep and improved physical function.

Side effects were recorded, with dizziness, headaches, fatigue, and nausea being the most common. Over 17% of patients stopped taking the medication early due to these issues. However, researchers observed no signs of drug abuse, dependence, or withdrawal among those who completed the trial. Chronic pain remains a leading reason for medical marijuana use. Unlike over-the-counter pain relievers or opioids—which carry risks of addiction and long-term side effects—this new drug offers a potential alternative. The findings add to growing evidence supporting cannabis-based treatments for persistent pain. A German parliamentary hearing, scheduled for February 23, 2026, will discuss proposed changes to medical cannabis prescribing rules. This could influence future approvals for similar medications in the country.

The trial results provide concrete data on the drug's effectiveness for lower-back pain. While side effects led some patients to discontinue use, the absence of addiction or withdrawal symptoms marks a key difference from opioids. Regulatory discussions in 2026 may shape whether this treatment becomes widely available in Germany.